Enjoy complimentary customisation on priority with our Enterprise License!
Uveal melanoma is one of the most common ocular melanomas. It arises from melanocytes in the iris, ciliary body, or choroid. Early diagnosis and local treatment are crucial, as the survival rate depends on them. However, approximately 50% of patients will develop metastatic disease with 6-12 months survival from metastatic diagnosis. The genomic analysis led to the development of gene-expression profiles, which predict metastatic progression effectively. The incidence of uveral melanoma varies by gender, race, and country. According to the National Cancer Institute, males have a higher incidence rate than females in the US with a ratio of 4.9 vs 3.7 per million of population. The incidence rate in the US remains lower than the rest of the world where it ranges between 5.3 and 10.9 cases per million of population. As a result, with increasing incidences of the disease, the drug development for uveal melanoma is expected to increase considerably in the forthcoming years.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for uveal melanoma. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of uveal melanoma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.
According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for uveal melanoma are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.